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Kathryn B. Garber1,*Let’s Start at the Very Beginning
You really can’t tackle a problem until you understand its
root cause. When that problem is cancer, physicians typi-
cally classify disease according to the cells or tissues
affected; in fact, however, there might be several different
underlying causes in each class. Besides this, some cancers
don’t fall neatly into a class, leaving an orphan group for
which the underlying mechanisms are likely to be dispa-
rate and difficult to uncover. This approach to classifying
cancer complicates treatment and means it is not unlikely
that a patient will receive a therapy to which their cancer
will not respond. Realizing that this is less than ideal,
Maxson et al. looked with a molecular lens at two hard-
to-classify cancers—chronic neutrophilic leukemia (CNL)
and atypical chronic myeloid leukemia (CML)–to see
whether they could do better. They performed deep
sequencing of the cancers and limited their search for rele-
vant mutations to a set of genes related to cellular
signaling. More than half of the samples they sequenced
had mutations in one of these, CSF3R, which encodes a
receptor for colony-stimulating factor. In vitro experi-
ments indicate that the mutations fall into two classes
that lead to different downstream-signaling consequences
that, in turn, make cells harboring these mutations suscep-
tible to different inhibitors. This background work served
as the impetus for treating a CNL patient with a drug
that was selected on the basis of the CSF3Rmutation found
in his cancer. The treatment reduced the patient’s white
cell and neutrophil counts and normalized the platelet
counts. Maybe starting at the beginning—with the muta-
tion that contributes to the cancer—will be a fruitful way
to group cancers and to tackle this disease.
Maxson et al. (2013). N. Engl. J. Med. 368, 1781–1789.
As if the FMR1-Related Disorders Weren’t
Complicated Enough.
Fragile X syndrome is the classic example of trinucleotide
repeat expansion that leads to a null mutation. If the
CGG repeat in the 50 region of FMR1 expands beyond a
certain size, methylation of the region transcriptionally si-
lences the gene, and the lack of expression of the encoded
protein leads to neurodevelopmental issues. A little over 10
years ago, it was noticed that people with a premutation-
sized CGG repeat at this locus suffered from tremors and
ataxia, and this was first attributed to a toxic RNA. Todd
et al. pondered the fact that this RNA toxicity doesn’t1Department of Human Genetics, Emory University School of Medicine, Atlan
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The Amjive with the observation that neuronal inclusions from
people with this disorder appear to be protein mediated.
Via experiments in flies, mice, cell cultures, and people,
they demonstrate that CGG premutations are translated,
through a non-AUG-initiated mechanism, into polygly-
cine- and polyalanine-containing products that are found
in the neuronal inclusions. Evidence inDrosophila suggests
that this repeat-associated non-AUG (RAN) translation
contributes to neuronal toxicity. If you’re keeping track,
that means no protein, too much RNA, and aberrant trans-
lation at this locus all seem to contribute various disease
phenotypes associated with FMR1 repeat expansion.
Todd et al. (2013). Neuron 78, 440–455.
Inhibitors of Altered IDH1 and IDH2 Induce Cellular
Differentiation
Two unexpected culprits in several cancer types, including
glioma, acute myeloid leukemia (AML), and sarcoma, are
IDH1 and IDH2, enzymes that normally convert isocitrate
to a-ketoglutarate. The cancer-associated alterations reside
in the catalytic pockets of IDH1 and IDH2 and confer them
with a novel activity that produces the R-enantiomer of
2-hydroxyglutarate (R-2HG). This product accumulates in
tumors and competitively inhibits a-ketoglutarate-depen-
dent dioxygenases, which in turn alters epigenetic patterns
and promotes malignancy. Because these changes confer a
nonnative function, the altered enzymes are plausible can-
didates for cancer therapy, particularly because there are
recurrent mutations in certain cancers. Wang et al. and
Rohle et al. each identified an inhibitor of one of these can-
cer-associated enzymes. Both inhibitors reduce production
of R-2HG and induce differentiation in cells containing the
relevant alteration. Beyond potential therapeutic applica-
tions, these inhibitors implicate altered IDH1 and IDH2
in the maintenance of cancer, not just as initial drivers of
a tumor.
Wang et al. (2013). Science 340, 622–626.
Rohle et al. (2013). Science 340, 626–630.
Using the Rare to Understand the Common
Several large genome-wide association studies have impli-
cated a number of genomic regions in body mass index
(BMI). Despite these successes, only a very minor fraction
of the variance in BMI can be explained by common
SNPs. Wheeler et al. figured that if they started with a sam-
ple from the extreme end of BMI, they might uncoverta, GA 30322, USA
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something new. In their severe early-onset obesity
(SCOOP) sample, they looked for association between
obesity and SNPs or copy-number variants (CNVs) across
the genome. Although some loci that they pulled out,
such as FTO andMC4R, were not surprises, they also found
novel associations with obesity. Single, rare CNVs were in
excess in the SCOOP sample, and an ingenuity pathway
analysis of the genes disrupted by the CNV highlighted
G-protein-coupled receptors. These more rare and extreme
cases of obesity thus provide new targets for investigation
of the ways in which we all regulate our BMI.
Wheeler et al. (2013). Nat. Genet. 45, 513–517.
Screening for All, Some, or Few
Only a minority of colon cancers are due to Lynch syn-
drome, but its implications for the patient and for the
family are substantial, in terms of both the recommended
screening and treatment strategies. Several different
published guidelines exist for the identification of at-risk
families. In general, the guidelines aim to maximize the
detection of affected families but in the most cost-effective
manner. Because some truly affected families won’t meet
these guidelines and because other families might just
fall through the cracks, some groups—such as the Evalua-838 The American Journal of Human Genetics 92, 837–838, June 6, 2tion of Genetic Applications in Practice and Prevention
(EGAPP) and the National Society of Genetic Coun-
selors—advocate universal Lynch syndrome screening in
patients newly diagnosed with colon cancer. To get a sense
of how well the family-history-based risk assessments are
used, Cross et al. collected information on >1,000 cases
of metastatic colon cancer via seven institutions in the
Cancer Research Network. They found that even when
the relevant risk information is collected, it is rarely used.
In this sample, Lynch syndrome screening was performed
for 3% of individuals, which is only a minority of those
whose health records indicate that they meet screening
guidelines. Beyond these cases with documented indica-
tion of Lynch syndrome risk, there were a number of other
families for whom complete risk analysis could not be per-
formed. Despite the fact that family-history information
was collected in 80% of cases overall, it often lacked essen-
tial detail for use in risk assessment, such as the age of onset
of cancers in the family. Because of the shortcomings in
the application of screening guidelines, this group of au-
thors recommends universal screening for Lynch syn-
drome so that fewer affected families will be missed.
Cross et al. (2013). Genet. Med. Published online May 2,
2013. http://dx.doi.org/10.1038/gim.2013.43.This Month in Our Sister JournalsHey, Are We Related?
Identifying segments of identity by descent (IBD) has a
number of applications for genome analysis, including
phasing data and detecting evidence of natural selection,
but it is computationally intensive to look for these seg-
ments in population data sets. Browning and Browningdescribe a newmethod for IBD-segment detection, Refined
IBD, and explore its performance on real and simulated
SNP and sequence data. This two-stage approach is effi-
cient and accurate and produces haplotype-phase output
that can be useful for certain downstream analyses.
Browning and Browning. (2013). Genetics 194, 459–471.013
